Related Experiment Video

Updated: Jun 25, 2026

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

15.9K

Rapid and Reliable HLA-B*59:01 Genotyping to Prevent Carbonic Anhydrase Inhibitor-Induced Severe Cutaneous Adverse

Ji Young Huh1, Yong Ju Song2, Geon Park3

  • 1Department of Laboratory Medicine, CHA Bundang Medical Center, Gyeonggi-do, Korea.

Annals of Clinical and Laboratory Science
|March 21, 2024
PubMed

Insights

A new duplex allele-specific PCR method accurately screens for the HLA-B*59:01 allele. This rapid and economical test can help prevent severe cutaneous adverse reactions from carbonic anhydrase inhibitors.

Area of Science:

  • Pharmacogenomics
  • Immunogenetics
  • Ophthalmology

Background:

  • Carbonic anhydrase inhibitors (CAIs) reduce intraocular pressure but can cause severe cutaneous adverse reactions (SCARs).
  • The human leukocyte antigen-B*59:01 (HLA-B*59:01) allele is strongly associated with CAI-induced SCARs.

Purpose of the Study:

  • To develop and validate a rapid, economical screening method for the HLA-B*59:01 allele.
  • To prevent SCARs associated with carbonic anhydrase inhibitor use.

Main Methods:

  • Duplex allele-specific polymerase chain reaction (PCR) with an internal control was used for HLA-B*59:01 genotyping.
  • The accuracy of the duplex allele-specific PCR method was validated against sequence-based typing (SBT) in 200 blood samples.

Main Results:

  • The duplex allele-specific PCR method achieved complete agreement with SBT results.
  • 50 HLA-B*59:01-positive and 150 HLA-B*59:01-negative results were correctly identified.

Conclusions:

  • Duplex allele-specific PCR is a rapid, reliable, and economical assay for screening the HLA-B*59:01 allele.
  • This screening method can aid in preventing carbonic anhydrase inhibitor-induced SCARs.
Abstract

Keywords:
HLA-B*59:01allele-specific PCRcarbonic anhydrase inhibitor hypersensitivitysequence-specific primerssevere cutaneous adverse reactions

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.5K
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation08:07

Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation

Published on: September 6, 2017

10.1K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug Toxicity: Allergic Reactions01:30

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...